Entero Healthcare announces equity allotment, strategic acquisitions, and executive change

Entero Healthcare Solutions Limited announced on November 12, 2025, the allotment of 2,030 equity shares of INR 10 each to eligible employees exercising options under the Entero Employee Stock Option Scheme 2023. This increases the company's paid-up equity share capital from INR 43,50,89,070 to INR 43,51,09,370, with shares issued at an exercise price of INR 804 per equity share, including a premium of INR 794.

Additionally, Entero Healthcare Solutions has approved the acquisition of an 80% stake in Bioaide Technologies Private Limited for INR 31.13 crore to INR 36 crore, and a 51% stake in Anand Chemiceutics Private Limited for INR 210 crore to INR 230 crore, both subject to adjustments. Bioaide Technologies, incorporated on August 13, 1996, operates in wholesale distribution of medical devices with a turnover of INR 557.82 mn in FY 2024-2025. Anand Chemiceutics, incorporated on September 20, 2022, also operates in the wholesale distribution of medical devices and allied products with a turnover of INR 4,749 mn in FY 2024-2025. These acquisitions align with Entero's core business and are expected to be completed by February 15, 2026, and financial year 25-26, respectively.

The company also reported the change in designation of Mr. Abhitesh Kumar from president – retail business & new initiatives to chief growth officer, effective November 12, 2025.